Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Trading Down 15.7 %

Pieris Pharmaceuticals stock opened at $13.60 on Thursday. Pieris Pharmaceuticals has a 52 week low of $6.20 and a 52 week high of $22.32. The stock has a market cap of $17.95 million, a P/E ratio of -1.12 and a beta of 0.61. The stock has a 50 day moving average of $15.59 and a 200-day moving average of $14.84.

Institutional Investors Weigh In On Pieris Pharmaceuticals

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. BML Capital Management LLC bought a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals comprises 0.4% of BML Capital Management LLC’s holdings, making the stock its 21st largest holding. BML Capital Management LLC owned about 3.19% of Pieris Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.